About CaaMTech
CaaMTech is a company based in Issaquah (United States) founded in 2018 by Andrew Chadeayne. CaaMTech has raised $23.35 million across 2 funding rounds from investors including Noetic Fund. The company has 7 employees as of December 31, 2024. CaaMTech offers products and services including Psychedelic Drug Research and 5-MeO-DMT Analog Development. CaaMTech operates in a competitive market with competitors including ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others.
- Headquarter Issaquah, United States
- Employees 7 as on 31 Dec, 2024
- Founders Andrew Chadeayne
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Caamtech, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$23.35 M (USD)
in 2 rounds
-
Latest Funding Round
$22 M (USD), Series A
Sep 08, 2021
- Investors
-
Employee Count
7
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CaaMTech
CaaMTech offers a comprehensive portfolio of products and services, including Psychedelic Drug Research and 5-MeO-DMT Analog Development.
Research on novel therapeutics for mental health via serotonin modulation.
Development of analogs targeting serotonin receptors for health applications.
People of CaaMTech
Unlock access to complete
Unlock access to complete
Funding Insights of CaaMTech
CaaMTech has successfully raised a total of $23.35M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $22 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CaaMTech
CaaMTech has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Noetic Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Noetic Fund is engaged in global investments in emerging health technologies.
|
Locked | Locked | Locked |
Investor details for CaaMTech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CaaMTech
Investment portfolio details for CaaMTech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CaaMTech
Detailed financials for CaaMTech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Caamtech Comparisons
Peer comparison for CaaMTech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CaaMTech
CaaMTech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Therapies for mental disorders, including psilocybin for depression, are developed.
|
|
| Locked | Locked | Locked |
Psychedelic-based therapies for brain health disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of neurological and psychiatric disorders
|
|
| Locked | Locked | Locked |
Psychedelic therapeutics for psychiatric disorders are developed and provided.
|
|
| Locked | Locked | Locked |
Psychedelic-derived therapeutics for mental illnesses are developed.
|
Detailed competitors of CaaMTech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Caamtech
Complete news archive for CaaMTech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CaaMTech
CaaMTech was founded in 2018 and raised its 1st funding round 2 years after it was founded.
CaaMTech is headquartered in Issaquah, United States. It is registered at Issaquah, Washington, United States.
Andrew Chadeayne is the current CEO of CaaMTech. They have also founded this company.
CaaMTech is a funded company, having raised a total of $23.35M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at CaaMTech is 7.
CaaMTech was founded in 2018 and is based in Issaquah, United States. Operations focus on the biotechnology sector, where psychedelic drug discovery and research services are developed. Additional offerings include psychedelic formulations, drug safety and efficacy screening, intellectual property management to support funding, and technological innovations for advancement in the field.
CaaMTech's top competitors include MindMed, COMPASS Pathways and Beckley Psytech.
CaaMTech offers Psychedelic Drug Research and 5-MeO-DMT Analog Development.
CaaMTech has 1 investor. Key investors include Noetic Fund.